Oncometabolite 2-hydroxyglutarate regulates anti-tumor immunity

Area of Science:

• Oncology
• Immunology
• Metabolic Regulation

Background:

• 2-hydroxyglutarate (2-HG) is an oncometabolite influencing tumor progression.
• 2-HG affects both adaptive (T cells) and innate immune cells (macrophages, NK cells, dendritic cells).
• Elevated 2-HG disrupts epigenetic regulation, genome integrity, HIF signaling, and metabolism by inhibiting α-KG-dependent dioxygenases (α-KGDDs).

Purpose of the Study:

• To review the metabolism and biological functions of 2-HG.
• To explore the impact of 2-HG on the tumor immune microenvironment (TIME).
• To examine the clinical applications of targeted 2-HG therapies in cancer immunotherapy.

Main Methods:

• Literature review focusing on 2-HG metabolism, function, and immune interactions.
• Analysis of studies investigating the role of 2-HG enantiomers (D-2-HG and L-2-HG) in cancer.
• Exploration of clinical data and research on targeted 2-HG therapies.

Main Results:

• 2-HG significantly impacts immune cell proliferation, activation, and differentiation.
• Inhibition of α-KGDDs by 2-HG contributes to tumorigenesis through epigenetic and metabolic dysregulation.
• Distinct biological functions of D-2-HG and L-2-HG offer therapeutic opportunities.
• Targeting 2-HG enantiomers demonstrates potential in enhancing antitumor immunity.

Conclusions:

• 2-HG plays a critical role in shaping the tumor immune microenvironment.
• Understanding the dual role of 2-HG enantiomers is key for developing effective cancer immunotherapies.
• Targeted therapies against 2-HG present a promising avenue for cancer treatment, though challenges remain.